Biomarker 14-3-3eta Reflects RA Disease Activity, Treatment Response
EULAR 2013: Data to support effectiveness of a new biomarker test for rheumatoid arthritis that is already on the market have now been reported in a public presentation.
Six New Insights About RA Treament from the AMPLE Trial
EULAR 2013: Two-year data from a head-to-head comparison of abatacept and adalimumab show them comparably effective for rheumatoid arthritis. But the former is less costly with fewer noteworthy adverse effects.
Azathioprine Not Linked to Flare Risk in Lupus Nephritis Pregnancies
EULAR 2013: Women with inactive lupus nephritis (LN) appear to be at low risk for renal flares if they replace mycophenolate mofetil with azathioprine during pregnancy to protect the fetus.
Quick Relapse After Stopping TNF Inhibitors in Peripheral Spondylitis
EULAR 2013: In a small Dutch study, most patients who stopped anti-tumor necrosis factor inhibitor therapy relapsed within a few months.
OK to Cut Back TNF-Alpha Blockers in Stable Ankylosing Spondylitis
EULAR 2013: Nearly half of patients with stable ankylosing spondylitis in a small study cut back their doses of TNF-alpha inhibitors by a third without getting worse.
In Primary Sjögrens, Hydroxychloroquine Ineffective in Short-Term
EULAR 2013: Hydroxychloroquine is often prescribed for primary Sjögren’s. But a randomized trial shows no evidence of short-term efficacy other than some biomarker changes.
International Consensus on Treatment Targets for Spondyloarthritis and Psoriatic Arthritis
EULAR 2013: Your assignment for patients who have ankylosing spondylitis and psoriatic arthritis: Partner with them as they strive for a normal life, says an expert task force.
By clicking Accept, you agree to become a member of the UBM Medica Community.